Lumos Pharma, Inc. (LUMO) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Lumos Pharma, Inc. faces a significant risk concerning the potential valueless expiration of the Contingent Value Rights (CVRs) offered to stockholders post-2024 Merger and Offer completion. These CVRs, linked to future cash payments contingent upon achieving certain milestone events related to LUM-201’s revenue and other transactions, carry no guarantee of payout. As the CVRs lack equity, voting, or dividend rights and are non-transferable except under specific conditions, their value is highly uncertain. Stockholders could see these rights expire worthless if the stipulated milestones are not met within the specified timeframe.
Overall, Wall Street has a Moderate Buy consensus rating on LUMO stock based on 1 Buy and 2 Holds.
To learn more about Lumos Pharma, Inc.’s risk factors, click here.
